H.R. 5429 · 118th Congress (2023–2025)
Medication Affordability and Patent Integrity Act
To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office.
CRS summary not yet available.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 5429’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Ann M. Kuster (D-NH-2)
- Cosponsors
1 cosponsor
1 original · 0 later
- Rep. Diana Harshbarger (R-TN-1)· Original · Sep 13, 2023
- Policy area
- Commerce
- Subjects
- Drug safety, medical device, and laboratory regulation
- Inflation and prices
- Intellectual property
- Manufacturing
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Sep 13, 2023 – Sep 15, 2023
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Medication Affordability and Patent Integrity Act
Display title, Short title · Introduced in House
To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office.
Official title · Introduced in House